SIRPA and cancer: Several immunotherapies aim to disrupt these interactions through the use of macrophage immune checkpoint (MIC) blockers (such as blocking antibodies against CD47 or antagonistic engineered SIRPα variants) to circumvent signaling that inhibits phagocytosis, enabling macrophages to engulf and clear cancer cells1,3–6,8,9.